Therapeutic ultrasound developer EDAP TMS announced that the U.K. National Institute for Health and Clinical Excellence (NICE) has published guidance regarding focal therapy using high-intensity focused ultrasound (HIFU) to treat localized prostate cancer.
The NICE International Procedure Guidance 424 highlights the potential for focal HIFU to avoid many of the complications of more radical treatment procedures for localized prostate cancer in appropriately selected patients. HIFU treatment is generally recommended for patients who have stages T1 to T2 localized prostate cancer who are not candidates for surgery or who failed radiotherapy treatment.
EDAP TMS also promoted a study presented at the International Symposium on Focal Therapy Imaging in Prostate and Kidney Cancer held in Durham, NC, from 6 to 8 June. Dr. E. Baco of Oslo University Hospital in Norway presented data regarding successful outcomes as a result of treatment of patients who had failed radiotherapy with its Ablatherm-HIFU system.
